Covid-19 News and Discussions


Virus that causes COVID-19 can damage heart even if heart tissue not directly affected​

Add topic to email alerts

Key takeaways:​

  • The SARS-CoV-2 virus, which causes COVID-19, can cause damage to the heart via inflammation triggered by the immune system.
  • This can happen even if there is no direct damage to heart tissues from the virus.
Among patients who died of acute respiratory distress syndrome associated with SARS-CoV-2, the virus that causes COVID-19, heart tissues were damaged even when they were not directly affected by the virus, researchers reported.

For the NHLBI-funded study, the researchers investigated whether COVID-19-related heart damage was caused by direct action on the heart from SARS-CoV-2 or resulted from systemic inflammation caused by the immune system’s response to SARS-CoV-2 infection among patients who died of acute respiratory distress syndrome (ARDS) as a result of COVID-19.

COVID variant
The SARS-CoV-2 virus, which causes COVID-19, can cause damage to the heart via inflammation triggered by the immune system. Image: Adobe Stock
“What this study shows is that after a COVID infection, the immune system can inflict remote damage on other organs by triggering serious inflammation throughout the body — and this is in addition to damage the virus itself has directly inflicted on the lung tissue,” Matthias Nahrendorf, MD, PhD, professor of radiology at Harvard Medical School, said in a press release. “These findings can also be applied more generally, as our results suggest that any severe infection can send shockwaves through the whole body.”

Nahrendorf and colleagues compared autopsy results, focusing on cardiac macrophages, of 21 people who died of ARDS as a result of COVID-19 and 33 people who died of other causes. They also conducted a study in mice determine what happens to cardiac macrophages after SARS-CoV-2 infection or lung injury not related to SARS-CoV-2.

Compared with people who died of other causes, in people who died of ARDS as a result of COVID-19, there were higher counts of total cardiac macrophages and a greater proportion of CCR2+ macrophages, which promote inflammation, Nahrendorf and colleagues found.

In mice, both infection with SARS-CoV-2 and lung injury not related to SARS-CoV-2 were associated with remodeling of cardiac resident macrophages and expansion of CCR2+ macrophages. In mice with lung injury not related to SARS-CoV-2, treatment with a tumor necrosis factor-alpha-inhibiting antibody reduced cardiac monocytes and CCR2+ macrophages and preserved cardiac function, and among those mice, those with preexisting HF were more likely to die, according to the researchers.

“Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2+ macrophage subset and that the associated cardiac phenotypes ... can be elicited by activating the host immune system even without viral presence in the heart,” the researchers wrote.

Reference:​

 

New Study Reveals Insights into Lack of Durability in COVID Antibody Response to Infections & Vaccines​

NewsArchive Pages2024 NewsNew Study Reveals Insights into Lack of Durability in COVID Antibody Response to Infections & Vaccines
March 20, 2024 | Jennifer Gonzales
lewis-sajadi-ihv-banner.jpg

Photo: Co-authors, George Lewis, PhD (left) and Mohammad Sajadi, PhD are researchers at the Institute of Human Virology (IHV)

Researchers at the IHV at the UMSOM published a new study in the Journal of Infectious Diseases investigating the short-lived antibody response following SARS-CoV-2, the virus that causes COVID.

Long-lived plasma cells are responsible for durable antibody responses that persist for decades after immunization or infection. For example, infection with measles, mumps, rubella, or immunization with vaccines against these contagions elicit antibody responses that can last for years or decades. By contrast, immunity against COVID from either a natural infection or a vaccine confers a much shorter-lived antibody response, only up to a few years at most. The mechanism underlying this problem, however, remained unknown.
“We know long-lived plasma cells can produce antibodies against specific pathogens for decades, so we wanted to investigate their role in COVID infection,” said study co-author Mohammad Sajadi, MD, Associate Professor of Medicine, Division of Clinical Care and Research, Institute of Human Virology.
The study by Dr. Sajadi and his colleagues examined the contribution of long-lived plasma cells in the bone marrow to anti-spike antibodies after COVID infection. They studied 20 individuals with a history of COVID infection but no vaccination. Bone marrow aspirates and plasma samples were analyzed to characterize antibody responses. The research found a deficient generation of spike-specific long-lived plasma cells in the bone marrow, offering insight into the short duration of antibody responses observed in recovering COVID patients.

George Lewis, PhD
George Lewis, PhD“The rapid waning of spike-specific antibodies we observed indicates a lack of durable antibody production after natural infection,”
said study co-author George Lewis, PhD, director of the Division of Vaccine Research, Institute of Human Virology. “This appears to be due to insufficient generation of long-lived plasma cells that would sustain antibody levels, a phenomenon we’ve noted before with certain viruses.”

Ten years ago, the researchers discussed the possible mechanisms for this problem with regards to HIV in a peer-reviewed publication and have been working on it since. (Like COVID vaccines, experimental HIV vaccines also confer short-lived immunity.) Their work on the poor persistence of antibody responses to the SARS-CoV-2 spike protein shows that the antibody persistence problem extends to COVID as well and that it is likely due to lack of long-lived antibody-secreting cells in the bone marrow.

Shyam Kottilil, MBBS, PhDShyam Kottilil, MBBS, PhDShyam Kottilil, PhD, Interim IHV Director, added, “Sustained antibody responses to viral infections are critical for vaccine development and long-term immunity. The presence of long-lived plasma cells in bone marrow is a crucial component for the generation of prolonged effective antiviral immunity. This study by Drs. Sajadi and Lewis and colleagues provide vital information about protracted immunity to COVID, which is a breakthrough in our understanding of antiviral immunity due to COVID and other viruses.”

The researchers say the findings will help inform the development of vaccines and therapeutics that can induce robust long-term antibody production against SARS-CoV-2 and HIV. New studies have been designed in people to work out the cellular and molecular basis of this problem.

Mark T. Gladwin, MD
Mark T. Gladwin, MD“This intriguing new study provides a possible explanation for why antibody responses to SARS-CoV-2 decay quickly,”
said Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore. “Future studies will be key to further investigate the cellular and molecular basis of why SARS-CoV-2 does not elicit long lived antibody secreting cells specific for the SARS-CoV-2 spike protein with the ultimate goal of correcting this deficit in future vaccine designs.”

The team aims to secure further funding to continue pursuing this critical area of vaccine research.
“We were fortunate to be able to study this problem in context of first exposure to a new human pathogen and disease,” said Dr. Sajadi. “We are grateful to our volunteer participants and colleagues, especially co-first authors Drs. Zahra Rikhtegaran Tehrani and Parham Habibzadeh, as well as Robin Flinko, whose efforts made this impactful study possible.”

About the Institute of Human Virology​

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland, and the University of Maryland Medical System, the IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology, and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders, most notably HIV, the virus that causes AIDS. For more information, visit ihv.org and follow us on Twitter @IHVmaryland.

About the University of Maryland School of Medicine​

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
 

Joint hypermobility linked to longer COVID-19 recovery time​


Pooja Toshniwal Paharia
By Pooja Toshniwal PahariaMar 20 2024Reviewed by Benedette Cuffari, M.Sc.
In a recent study published in BMJ Public Health, researchers investigated whether generalized joint hypermobility (GJH), which indicates varying connective tissue, was associated with self-reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection recovery failure.
ImageForNews_775093_17109745555056950.jpg
Study: Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case-control evidence from the British COVID Symptom Study Biobank. Image Credit: BigBlueStudio / Shutterstock.com

Background​

Long coronavirus disease 2019 (COVID-19) presents a severe therapeutic issue and public health burden, with symptoms ranging from fatigue and trouble focusing to muscular pains and shortness of breath. To date, over 200 symptoms have been associated with delayed recovery after acute SARS-CoV-2 infection. The potentially deleterious effects associated with long COVID-19, combined with the prevalence of SARS-CoV-2 infection history among the general population, emphasize the importance of identifying factors predisposing an individual to long COVID.
Demographic variables such as age and female sex, as well as pre-existing activity-limiting health disorders or impairments like fibromyalgia, irritable bowel syndrome, migraines, allergies, anxiety, depression, and back pain, increase the likelihood of prolonged COVID-19.
Recent research has identified that joint hypermobility contributes to incomplete recovery after SARS-CoV-2 infection. However, further research is needed to elucidate the etiology of long COVID and identify cost-effective and timely therapeutics for patients.

About the study​

In the present prospective-type observational study, researchers investigate whether widespread joint hypermobility is related to an increased risk of not fully recovering from SARS-CoV-2 infection.
To this end, the researchers examined the United Kingdom COVID-19 Symptom Study Biobank (CSSB) data, linked with demographic information, COVID-19 reports, and symptom ratings from ZOE Global's COVID-19 Symptom Study digital application. Researchers from Massachusetts Hospital, Uppsala and Lund Universities, and King's College London created the mobile application.
During August 2022, 81% of respondents experienced a minimum of one COVID-19-related illness and self-reported their recovery status. All study participants completed a five-component Hakim and Grahame questionnaire (5PQ) to determine widespread joint hypermobility.
The primary research outcome was a lack of self-documented recovery from SARS-CoV-2 infection. Secondary outcomes included 5PQ scores and self-documented fatigue levels.
Binary logistic regression analysis was performed to determine whether widespread joint hypermobility predicted non-recovery after SARS-CoV-2 infection. Age, gender, ethnicity, socioeconomic situation, educational attainment, and received COVID-19 vaccinations were considered as potential variables in the sequential models.

Related Stories​

Linear regression was used to investigate the relationship between generalized joint hypermobility and fatigue. Furthermore, mediation studies using Hayes' technique allowed the researchers to explore potential mediation of the association between widespread joint hypermobility and COVID-19 non-recovery by fatigue levels.

Study findings​

Among 3,064 individuals who reported a minimum of one SARS-CoV-2-related infection, data on self-documented COVID-19 recovery were accessible for 2,854 participants, 82% of whom were female and 97% identified as white, with an average age of 58 years.
Among 32% of the study cohort who reported incomplete recovery from acute COVID-19, 269 individuals exhibited widespread joint hypermobility, 29% of whom were female. Among recovered individuals, 439 of 1,940 patients experienced widespread joint hypermobility.
Generalized joint hypermobility was not significantly associated with the reported SARS-CoV-2 infection risk. Nevertheless, joint hypermobility was strongly associated with incomplete recovery from acute COVID-19, with an odds ratio (OR) of 1.4. This association persisted in sequential modeling studies controlling for age, gender, ethnicity, educational attainment, multiple deprivation index, and COVID-19 vaccination doses received with an OR of 1.3.
Hypermobility also strongly predicted greater fatigue levels in models that controlled for all factors. Fatigue levels influenced the relationship between widespread joint hypermobility and COVID-19 non-recovery.

Conclusions​

The study findings indicate that individuals with widespread joint hypermobility are 30% more likely to not recover from acute COVID-19. These observations provide critical information needed to identify long COVID phenotypes for screening, appropriate patient classification, and personalized treatment implementation.
Taken together, the current study emphasizes the importance of stratified individualized healthcare for individuals, which influences policy and interdisciplinary services for individuals with long-term COVID and related illnesses. These findings also have implications for clinical practice, future research, and population healthcare, including precision techniques.
There remains an urgent need to investigate predisposing variables and comorbidities associated with joint hypermobility. Future research is also needed to explore the role of pre-existing illnesses as possible risk factors, particularly those linked with numerous physical symptoms, including larger sample sizes, more diverse populations, and a stringent long COVID definition to improve the generalizability and validity of the study findings.
 

Getting Reluctant Patients to 'Yes' on COVID Vaccination​

David Brzostowicki
March 20, 2024

No matter how much we'd like to leave it in the dust, COVID-19 remains prevalent and potent. Tens of thousands of people still contract COVID per week in the United States. Hundreds die. And those who don't may still develop long COVID.
Pleas from public health officials for people to get a COVID vaccine or booster shot have been ignored by many people. About 80% of eligible Americans haven't taken any kind of COVID booster. Meantime, the virus continues to mutate, eroding the efficacy of the vaccine's past versions.
How to get more people to get the jab? Vaccine hesitancy, said infectious disease specialist William Schaffner, MD, is likely rooted in a lack of trust in authority, whether it's public health officials or politicians.

Schaffner, a professor of infectious diseases at the Vanderbilt University School of Medicine, Nashville, Tennessee, and former medical director of the National Foundation for Infectious Diseases, recommended five strategies physicians can try when discussing the importance of staying up to date on COVID vaccines with patients.

#1: Be Patient With Your Patient

First and foremost, if doctors are feeling reluctance from their patients, they need to know "what they shouldn't do," Schaffner said.




When a patient initially doesn't want the vaccine, doctors shouldn't express surprise. "Do not scold or berate or belittle. Do not give the impression the patient is somehow wrong or has failed a test of some sort," Schaffner said.
Step back and affirm that they understand what the patient is saying so they feel reassured, even if they don't agree or it's based on falsehoods about the vaccine.
He said patients need to feel "the doctor heard them, it's okay to tell the doctor this." When you affirm what the patient says, it puts them at ease and provides a smoother road to eventually getting them to say "yes."
But if there's still a roadblock, don't bulldoze them. "You don't want to punish the patient…let them know you'll continue to hear them," Schaffner said.

#2: Always Acknowledge a Concern

Fear of side effects is great among some patients, even if the risks are low, Schaffner said. Patients may be hesitant because they're afraid they'll become one of the "two or three in a million" who suffer extremely rare side effects from the vaccine, Schaffner said.

In that case, doctors should acknowledge their concern is valid, he said. Never be dismissive. Ask the patients how they feel about the vaccine, listen to their responses, and let them know "I hear you. This is a new mRNA vaccine…you have concern about that," Schaffner said.
Doctors can segue into how there's little reason to wait for some elusive perfectly risk-free vaccine when they can help themselves right now.
"The adverse events that occur with vaccines occur within 2 months [and are typically mild]. I don't know of a single vaccine that has genuinely long-term implications," Schaffner said. "We should remember that old French philosopher Voltaire. He admonished us: Waiting for perfection is the great enemy of the current good."

#3: Make a Strong Recommendation

Here's something that may seem obvious: Don't treat the vaccine as an afterthought. "Survey after survey tells us this…it has everything to do with the strength of the recommendation," Schaffner said.

Doctors typically make strong treatment recommendations such conditions as diabetes or high blood pressure, but "when it comes to vaccines, they're often rather nonchalant," he said.
If a patient is eligible for a vaccine, doctors should tell the patient they need to get it — not that you think they should get it. "Doctors have to make a firm recommendation: 'You're eligible for a vaccine…and you need to get it…you'll receive it on your way out.' It then becomes a distinct and strong recommendation," he said.

#4: Appeal to Patients' Hearts, Not Their Minds

In the opening of Charles Dickens's novel "Hard Times," the stern school superintendent, Mr Gradgrind, scolds his students by beating their brow with the notion that, "Facts alone are wanted in life. Plant nothing else and root out everything else."

The idea that facts alone can sway a vaccine-resistant patient is wrong. "It often doesn't happen that way," Schaffner said. "I don't think facts do that. Psychologists tell us, yes, information is important, but it's rarely sufficient to change behavior."
Data and studies are foundational to medicine, but the key is to change how a patient feels about the data they're presented with, not how they think about it. "Don't attack their brain so much but their heart," Schaffner said.
Schaffner has stressed with his patients that the COVID vaccine has become "the social norm," suggesting virtually everyone he knows has received it and had no problem.
Once questions have been answered about whether the vaccine works and its various side effects, doctors could remind the patient, "You know, everyone in my office is getting the vaccine, and we're trying to provide this protection to every patient," he said.
You're then delving deeper into their emotions and crossing a barrier that facts alone can't breach.

#5: Make it Personal

Lead by example and personalize the fight against the virus. This allows doctors to act as if they're building an alliance with their patients by framing the vaccine not as something that only affects them but can also confer benefits to a broader social circle.

Even after using these methods, patients may remain resistant, apprehensive, or even indifferent. In cases like these, Schaffner said it's a good idea to let it go for the time being.
Let the patient know they "have access to you and can keep speaking with you about it" in the future, he said. "It takes more time, and you have to be cognizant of the nature of the conversation."
Everybody is unique, but with trust, patience, and awareness of the patient's feelings, doctors have a better shot at finding common ground with their patients and convincing them the vaccine is in their best interest, he said.
 

Could Double-Jointed Folk Face Higher COVID Risks?​


By HealthDay
|
March 20, 2024, at 7:39 a.m.
Save
More

Could Double-Jointed Folk Face Higher COVID Risks?
More
By Dennis Thompson and Carole Tanzer Miller HealthDay Reporters
HD1710856228998origin.jpg

HEALTHDAY

WEDNESDAY, March 20, 2024 (HealthDay News) -- People who are double-jointed might be at increased risk of developing long COVID, a new study reports.
Double-jointed folks are 30% more likely to not fully recover from COVID-19 infection, compared with those who are less flexible, researchers report in the journal BMJ Public Health.
They also are more likely to experience the persistent fatigue associated with long COVID, results show.

These findings demonstrate how COVID attacks different parts of the body, taking advantage of whatever it finds, researchers said.

U.S. Cities With the Most Homelessness​

A man walks past tents housing the homeless on the streets in the Skid Row community of Los Angeles, California on April 26, 2021. - A federal judge overseeing a lawsuit that seeks to end the city's Skid Row homelessness crisis isn't backing down from his order requiring that all indigent persons in the area be offered shelter within six months. US District Judge David O. Carter is opening the door for more discussions by setting additional hearing dates and clarifying some portions of his ruling. (Photo by Frederic J. BROWN / AFP) (Photo by FREDERIC J. BROWN/AFP via Getty Images)
View All 28 Slides
Long COVID is more likely in people with health problems also shared among the double-jointed, researchers noted – fibromyalgia, irritable bowel syndrome, migraine, allergies, anxiety, depression and back pain.
The presence of what the researchers called "joint laxity" gives "an important clue to differences in connective tissue composition that can affect multiple bodily systems,” explained the research team. It was led by Dr. Jessica Eccles, a clinical neuroscientist with Brighton and Sussex Medical School in Brighton, U.K.
For the study, researchers analyzed data on more than 3,000 participants in a COVID symptom study.
About 1 in 3 people said they had not fully recovered from their last bout with COVID, and among them nearly 30% were double-jointed.
After accounting for other risks, double-jointedness was strongly associated with a failure to fully recover from COVID infection and higher levels of fatigue.
Long COVID is probably a syndrome of different symptoms that the coronavirus causes within the immune, inflammatory, nervous, respiratory and cardiovascular systems of human beings, researchers said.

Very flexible joints could be one route by which COVID does lasting harm, the research team concluded.
The study does not prove that double-jointedness is a cause of long COVID, only that there's a link. Researchers also noted that the study population was not diverse; most participants were white women.
More information
Harvard Medical School has more on long COVID risk factors.
SOURCE: BMJ, news release, March 19, 2024
Copyright © 2024 HealthDay. All rights reserved.
 

AI can now detect COVID-19 in lung ultrasound images

Date:​
March 20, 2024​
Source:​
Johns Hopkins University​
Summary:​
Artificial intelligence can spot COVID-19 in lung ultrasound images much like facial recognition software can spot a face in a crowd, new research shows. The findings boost AI-driven medical diagnostics and bring health care professionals closer to being able to quickly diagnose patients with COVID-19 and other pulmonary diseases with algorithms that comb through ultrasound images to identify signs of disease.​
Share:​
FULL STORY

Artificial intelligence can spot COVID-19 in lung ultrasound images much like facial recognition software can spot a face in a crowd, new research shows.
The findings boost AI-driven medical diagnostics and bring health care professionals closer to being able to quickly diagnose patients with COVID-19 and other pulmonary diseases with algorithms that comb through ultrasound images to identify signs of disease.
The findings, newly published in Communications Medicine, culminate an effort that started early in the pandemic when clinicians needed tools to rapidly assess legions of patients in overwhelmed emergency rooms.
"We developed this automated detection tool to help doctors in emergency settings with high caseloads of patients who need to be diagnosed quickly and accurately, such as in the earlier stages of the pandemic," said senior author Muyinatu Bell, the John C. Malone Associate Professor of Electrical and Computer Engineering, Biomedical Engineering, and Computer Science at Johns Hopkins University. "Potentially, we want to have wireless devices that patients can use at home to monitor progression of COVID-19, too."
The tool also holds potential for developing wearables that track such illnesses as congestive heart failure, which can lead to fluid overload in patients' lungs, not unlike COVID-19, said co-author Tiffany Fong, an assistant professor of emergency medicine at Johns Hopkins Medicine.
"What we are doing here with AI tools is the next big frontier for point of care," Fong said. "An ideal use case would be wearable ultrasound patches that monitor fluid buildup and let patients know when they need a medication adjustment or when they need to see a doctor."
The AI analyzes ultrasound lung images to spot features known as B-lines, which appear as bright, vertical abnormalities and indicate inflammation in patients with pulmonary complications. It combines computer-generated images with real ultrasounds of patients -- including some who sought care at Johns Hopkins.
"We had to model the physics of ultrasound and acoustic wave propagation well enough in order to get believable simulated images," Bell said. "Then we had to take it a step further to train our computer models to use these simulated data to reliably interpret real scans from patients with affected lungs."
Early in the pandemic, scientists struggled to use artificial intelligence to assess COVID-19 indicators in lung ultrasound images because of a lack of patient data and because they were only beginning to understand how the disease manifests in the body, Bell said.
Her team developed software that can learn from a mix of real and simulated data and then discern abnormalities in ultrasound scans that indicate a person has contracted COVID-19. The tool is a deep neural network, a type of AI designed to behave like the interconnected neurons that enable the brain to recognize patterns, understand speech, and achieve other complex tasks.
"Early in the pandemic, we didn't have enough ultrasound images of COVID-19 patients to develop and test our algorithms, and as a result our deep neural networks never reached peak performance," said first author Lingyi Zhao, who developed the software while a postdoctoral fellow in Bell's lab and is now working at Novateur Research Solutions. "Now, we are proving that with computer-generated datasets we still can achieve a high degree of accuracy in evaluating and detecting these COVID-19 features."
The team's code and data are publicly available here: https://gitlab.com/pulselab/covid19

Story Source:
Materials provided by Johns Hopkins University. Original written by Roberto Molar Candanosa. Note: Content may be edited for style and length.
 

Not even Antarctica could stop COVID: It's a crucial lesson​

by F.D. Flam, Bloomberg Opinion

Antarctica
Credit: Unsplash/CC0 Public Domain
COVID-19 wasn't supposed to get to Antarctica. If any place had a hope of keeping the virus out, it would be a continent with no permanent residents and an annual visiting population of only 5,000. And every control measure was in place—testing, a strict quarantine of everyone visiting, as well as lots of deep sanitation, masks and social distancing.

And yet the virus got there in December 2020, less than a year into the pandemic. It arrived at the Chilean base first, spreading to at least 36 people. It later reached the Belgian base, and the Argentinian base, as well as French and British outposts. In 2022, there was a big outbreak at the US McMurdo station, one at New Zealand's Scott base and even a few cases at the South Pole.
Four years after the start of the pandemic, the frozen continent holds a lesson for the world in how much control we ever had over COVID. Back in March 2020, leaders worldwide talked about getting things under control, without thinking through what this entailed.
COVID in Antarctica "tells us a lot about human arrogance in terms of being above nature and being able to manage all that happens in nature," said Daniela Liggett, a social scientist at the University of Canterbury who studies Antarctic politics and environmental management. "We couldn't even lock away this one piece of the planet where nobody lives and protect it from the virus." She explored the situation and its implications in a paper in the journal Science Advances.
Humanity can control what we dump into the environment and emit into the atmosphere. We can exert some control over activities that might transfer animal viruses to humans. But after the fact, it's nearly impossible to hoover up plastic pollution or cool our artificially warmed planet or control a virus that's already spread far and wide.

By the end of March 2020, COVID had reached every continent on the planet except for Antarctica, where the summer research season was underway. Before that season was over, most research and tourism to the continent was paused. Scientists scheduled to continue experiments or collect field data were kept out. As months went by, Antarctica went into its dark, cold winter season, and its small skeleton crews remained isolated.
When the next summer research season began in late 2020, however, some researchers and support staff were allowed to return following a strict quarantine. To get to the New Zealand base, people had to be tested and then hole up alone in a hotel room for two weeks, Liggett said, while continuing to undergo daily testing. Once vaccines became available to the general public, the US programs and others required everyone to be up to date on their shots.
Despite all this, disease found a way to sneak in and spread.
That doesn't mean that Antarctica's policy was a failure. It showed the futility of going for total containment or elimination by cancelling activities and then using quarantines, testing and masks. But rejecting all those measures would have increased the number of cases and the odds that people would die. Before the vaccines became available, it wasn't all that rare for seemingly healthy people to get a severe case. Such cases would be more likely to turn deadly in a remote outpost far from a hospital.
The decision to resume Antarctic research activity struck a balance between the risks of disease and the benefits of conducting research that can't be done elsewhere. The few Antarctic regions not covered in ice are full of lakes where scientists have found improbable life forms, giving them clues to the way life might survive on other worlds.
Some scientists are monitoring the effects of global warming on the ice sheets, and others are monitoring the accumulation of microplastics and PFAS (forever chemicals) on the Antarctic ice and in the surrounding seas. Others study ghostly particles or astrophysical phenomena.
Shutting down everything even for part of one season had consequences. Careers were derailed, said Liggett, because researchers couldn't get to the continent to finish field studies or experiments. For young investigators in competitive fields, that could make the difference between getting established and starting over.
Now, she said, researchers in Antarctica don't spend all that much time worrying about COVID. They've moved on—because that's what everyone is doing worldwide. And doing research in such extreme conditions has always required some appetite for balancing risk and reward.
Today, fact checkers, ignoring the complexity of the real world, try to argue that the virus is "under control" in the US despite a continued weekly death toll in the hundreds. But what counts as "under control" is inherently subjective and often politically malleable.
 

People with hypermobility may be more prone to long Covid, study suggests​

People with excessive flexibility 30% more likely to say they had not fully recovered from Covid, research finds

Linda Geddes Science correspondent
Tue 19 Mar 2024 22.30 GMT
Share


People with excessively flexible joints may be at heightened risk of long Covid and persistent fatigue, research suggests.
Hypermobility is where some or all of a person’s joints have an unusually large range of movement due to differences in the structure of their connective tissues that support, protect and give structure to organs, joints and other tissues.

Up to 20% of adults are hypermobile and many of them are completely healthy. Hypermobility can even be beneficial, with many musicians and athletes having very flexible joints. However, it can also create problems, such as an increased propensity to pain, fatigue, joint injuries and stomach or digestive problems.

Dr Jessica Eccles, from Brighton and Sussex Medical School, and her colleagues had been investigating a potential link between hypermobility, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (a condition that causes pain all over the body), when the Covid pandemic hit.
“We started thinking, if hypermobility is potentially a factor in ME/CFS, is it also a factor in long Covid?” Eccles said.

Woman sits on bed looking out of window.
Summer picks: are we any closer to understanding long Covid? – podcast
Read more

She teamed up with researchers from King’s College London and examined data from 3,064 participants in the Covid symptom study (now the Zoe health study) to see if they had hypermobile joints, had fully recovered from their last bout of Covid, and if they were experiencing persistent fatigue.
The research, published in BMJ Public Health, found that people with hypermobile joints were about 30% more likely to say they hadn’t fully recovered from Covid-19 than those with normal joints, and were significantly more likely to be affected by high levels of fatigue.
Although the study doesn’t prove that hypermobility caused their illness, there is a plausible mechanism through which it could contribute symptoms such as fatigue, brain fog and postural tachycardia syndrome (PoTS) – where people’s heart rates rapidly increase when they stand up.

Eccles added: “We’ve known for some time that PoTs is closely associated with hypermobility.” The theory is that loose connective tissue in people’s veins and arteries can cause blood to pool in their tissues, meaning the heart has to work harder to pump blood to their brains when they stand up, triggering symptoms such as palpitations and dizziness.
“It may be that some of these abnormalities were always there, but Covid unmasked them in a vulnerable person,” Eccles said.
One theory she is investigating is whether reduced blood flow to the brain could contribute to brain fog and fatigue in a subset of individuals. However, there are other possibilities.
Eccles said: “We also know that hypermobility is related to conditions such as ADHD and autism, and ME/CFS and fibromyalgia, so fatigue might be a consequence of that.”
She stressed that long Covid was unlikely to be a single entity, but said a better understanding of the link with hypermobility may aid the development of new treatments.
“What this work suggests is that there may be a subgroup of people with long Covid who are more likely to be hypermobile,” she said.
“This is important to identify. It may be that some of the same things that help people with hypermobility and pain, such as strengthening and supporting the core muscles, could help across the board.”
This article was amended on 20 March 2024. Dr Jessica Eccles is from Brighton and Sussex Medical School, not the University of Sussex as we said in an earlier version.
 

US life expectancy rose in 2022 as deaths due to COVID dropped: CDC​

COVID fell from the third- to fourth-leading cause of death.
ByMary Kekatos
March 21, 2024, 12:01 AM




covid-gty-er-240320_1710966589987_hpMain_16x9.jpg


3:11

What we learned about long COVID 4 years later
What we learned about long COVID 4 years later
Millions of Americans are still experiencing long COVID more than four years since the glo...Show More


Life expectancy in the United States increased in 2022 after two years of decline, according to new final federal mortality data.
In a report published early Thursday by the Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS), data showed life expectancy at birth was 77.5 years in 2022.
While life expectancy hasn't reached pre-pandemic levels, it marked an increase of 1.1 years from 76.4 years in 2021.

MORE: US life expectancy falls to lowest levels since 1996 due to COVID, drug overdoses: CDC​




In total, there were 3.27 million deaths recorded in the U.S. in 2022, about 184,374 fewer deaths than recorded in 2021.
The death rate in the U.S. decreased from 879.7 deaths per 100,000 in 2021 to 798.8 in 2022, a 9.2% drop.
ABC News Illustration

Life Expectancy in the United States
National Center for Health Statistics, National Vital Statistics System
The report found the top 10 leading causes of death stayed the same from 2021 to 2022 but some causes changed ranks. Heart disease and cancer remained the two leading causes of death, respectively.
COVID-19 fell to the fourth-leading cause of death in 2022 while unintentional injuries took the number three spot.
Additionally, the number of deaths for which the virus was the underlying cause of death dropped by 55.3% from 416,893 in 2021 to 186,552 in 2022.
All of the top 10 leading causes of death saw a drop in death rates except kidney disease -- the ninth-leading cause -- which increased by 1.5%, from 13.6 per 100,000 deaths in 2021 to 13.8 per 100,0000 deaths in 2022.
When broken down by sex, males and females saw roughly the same increase in life expectancy from 2021 to 2022 with males increasing by 1.3 years from 73.5 years to 74.8 years and females increasing by 0.9 years from 79.3 years to 80.2 years.

MORE: Life expectancy dropped in 2020 in every US state, mainly due to COVID: CDC​




Every racial/ethnic group saw a decrease in death rates for both males and females. American Indian/Alaskan Native males had the highest death rates in 2022 but also saw the biggest drop in a year, decreasing 15.9% from 1,717.5 per 100,000 deaths to 1,444.1 per 100,000.
By age, death rates decreased for almost every age group except among children. The 1-4 age group saw death rates increase 12% from 25.0 deaths per 100,000 in 2021 to 28.0 per 100,000 deaths in 2022 and the 5-14 age group saw a 7% increase from 14.3 deaths per 100,000 in 2021 to 15.3 per 100,000 deaths in 2022.
A 2023 study found child and adolescent mortality rates had dropped due to decreases in childhood disease but have been increasing recently -- primarily due to increases in homicides, accidental drug overdoses, car accidents and suicides between ages 10 and 19.
Meanwhile, infant mortality increased by 3.1% from 543.6 infant deaths per 100,000 live births in 2021 to 560.4 in 2022.
PHOTO: People visit the 'In America: Remember' public art installation near the Washington Monument on the National Mall, Sept. 18, 2021, in Washington, D.C.

People visit the 'In America: Remember' public art installation near the Washington Monu...Show more
Kent Nishimura/Los Angeles Times via Getty Images
Congenital malformations were the leading cause of infant death in 2022 followed by low birth weight; sudden infant death syndrome; unintentional injuries; maternal complications; cord and placental complications; bacterial sepsis of newborn; respiratory distress of newborn; intrauterine hypoxia and birth asphyxia; and diseases of the circulatory system, respectively. Additionally, the report said the top 10 leading causes of death accounted for 65.2% of all infant deaths in the U.S. in 2022.
It comes as a separate NCHS report, also released on Thursday, found rates of drug overdose deaths -- despite quadrupling over the last two decades, becoming one of the leading causes of injury death in the U.S. -- did not significantly change from 2021 to 2022.
Between 2021 and 2022, the death rate involving synthetic opioids other than methadone -- such as fentanyl -- increased by 4.1% from 21.8 per 100,000 to 22.7 per 100,000, while rates for deaths involving heroin, natural and semisynthetic opioids and methadone declined.
 

COVID-19 levels low in Ottawa as flu sticks around​

The Kingston area again has a high respiratory risk​

Andrew Foote · CBC News · Posted: Mar 21, 2024 11:22 AM EDT | Last Updated: 8 hours ago
Someone fishes in a partially thawed lake on a sunny day.

As the ice melts, someone casts a fishing line in Dows Lake in Ottawa in April 2023. This year's flu season has stretched on much longer than the last one, with wastewater readings remaining very high in the nation's capital. (Adrian Wyld/The Canadian Press)

Social Sharing​

  • Facebook
  • X
  • Email
  • Reddit
  • LinkedIn
Recent developments:
  • Ottawa's COVID-19 numbers are low.
  • Some flu trends are still seen as very high.
  • That city's RSV levels are more moderate.
  • The Kingston area again has a high respiratory risk.
  • Four more COVID deaths have been reported.

The latest​

The weekly respiratory update from Ottawa Public Health (OPH) shows COVID-19 levels are lower than its two other closely tracked viruses.
COVID is low across the update's four categories, while RSV is more moderate.
Flu wastewater readings and hospitalizations remain very high as this flu season stretches much later than the last one.
None of the trends OPH monitors are rising, however.
OPH says the city's health-care institutions remain at high risk from respiratory illnesses, as they've been since the end of August. This will be the case until respiratory trends are low again.
Experts recommend people cover coughs, wear masks, keep hands and often-touched surfaces clean, stay home when sick and keep up with COVID and flu vaccines to help protect themselves and vulnerable people.

COVID-19 in Ottawa​

Ottawa's coronavirus wastewater average had been dropping for about 10 days as of March 18 to its lowest level since July.
A chart of the level of coronavirus in Ottawa's wastewater since March 2023.

Researchers have measured and shared the amount of novel coronavirus in Ottawa's wastewater since June 2020. This is the data for the last year. (613covid.ca)
The weekly average test positivity rate in the city is seven per cent. There are 14 new COVID-related hospitalizations in the city and the active COVID outbreak count is six.
There have been two more COVID deaths reported in the capital. OPH's next COVID vaccination update is expected in early April.

Across the region​

The Kingston area health unit is back in a high-risk respiratory time. Its trends are mostly stable, but local wastewater readings and the number of outbreaks have edged upward.
The Eastern Ontario Health Unit (EOHU) still rates its overall respiratory risk as moderate and stable.
Hastings Prince Edward (HPE) Public Health's weekly COVID hospital average remains at three. Its flu activity is low.
Western Quebec drops to 17 hospital patients who have tested positive for COVID. The province reports one more COVID death there.
Leeds, Grenville and Lanark (LGL) data goes up to March 10, when its trends were mostly dropping. A COVID death was added in its weekly update.
Renfrew County's next update is expected on Thursday.
 

Quebec public health institute publishes COVID-19 vaccination recommendations​

A woman receives a COVID-19 booster vaccine dose at the Olympic Stadium in Montreal, Monday, Dec. 27, 2021. (Graham Hughes, The Canadian Press)
A woman receives a COVID-19 booster vaccine dose at the Olympic Stadium in Montreal, Monday, Dec. 27, 2021. (Graham Hughes, The Canadian Press)

The Canadian Press
Staff
Contact
Published March 21, 2024 6:26 p.m. EDT
Share

The COVID-19 situation in Quebec is continuing to evolve, and certain population groups remain more vulnerable to the virus. This week, the Quebec Public Health Institute (INSPQ) published its vaccination recommendations for the spring of 2024.
People vaccinated against COVID-19 are less likely to develop a serious illness, but this protection gradually diminishes over the six months following vaccination. A booster dose is, therefore, necessary to maintain adequate protection, the INSPQ pointed out in its most recent advisory.

Serious complications from COVID-19 are much more common in people aged 80 and over. In this age group, around one infected person in 30 needs to be hospitalized.
In the 60 to 79 age group, the frequency of hospitalizations and deaths is lower, except for people living with a chronic illness.

RELATED STORIES​

A booster dose in the spring of 2024 could prevent "an appreciable number" of serious cases of COVID-19 among the most vulnerable, the INSPQ said.
The institute cautions, however, that the precise contribution of such a vaccination remains difficult to assess "given the paucity of efficacy studies specific to the XBB.1.5 monovalent vaccine and the possibility that variants increasingly distant from the vaccine strain will circulate during 2024."
On the basis of this information, the Quebec Immunization Committee (CIQ) is recommending a dose of monovalent XBB.1.5 vaccine in the spring for seniors aged 80 and over, as well as for people who are immunocompromised or on dialysis.
This recommendation also applies to residents of long-term care centres (CHSLDs) and residences for the elderly (RPAs).
According to INSPQ data, as of March 19, 661 people currently in hospital had tested positive for SARS-CoV-2, including both old and new cases.
 

New Covid-19 variant circulates in Kenya​


 

Yes, you can use at-home COVID tests past the expiration date, in some cases​


 

Road accidents rival Covid-19 in terms of fatalities: CS Kindiki​


 

New research seeks to understand risk factors for long COVID in pregnant women​


 

Users who are viewing this thread

Country Watch Latest

Back
Top